AHR and GPER mediate the stimulatory effects induced by 3-methylcholanthrene in breast cancer cells and cancer-associated fibroblasts (CAFs).


Journal

Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647

Informations de publication

Date de publication:
01 Aug 2019
Historique:
received: 01 05 2019
accepted: 23 07 2019
entrez: 3 8 2019
pubmed: 3 8 2019
medline: 10 1 2020
Statut: epublish

Résumé

The chemical carcinogen 3-methylcholanthrene (3MC) binds to the aryl hydrocarbon receptor (AHR) that regulates the expression of cytochrome P450 (CYP) enzymes as CYP1B1, which is involved in the oncogenic activation of environmental pollutants as well as in the estrogen biosynthesis and metabolism. 3MC was shown to induce estrogenic responses binding to the estrogen receptor (ER) α and stimulating a functional interaction between AHR and ERα. Recently, the G protein estrogen receptor (GPER) has been reported to mediate certain biological responses induced by endogenous estrogens and environmental compounds eliciting an estrogen-like activity. Molecular dynamics and docking simulations were performed to evaluate the potential of 3MC to interact with GPER. SkBr3 breast cancer cells and cancer-associated fibroblasts (CAFs) derived from breast tumor patients were used as model system. Real-time PCR and western blotting analysis were performed in order to evaluate the activation of transduction mediators as well as the mRNA and protein levels of CYP1B1 and cyclin D1. Co-immunoprecipitation studies were performed in order to explore the potential of 3MC to trigger the association of GPER with AHR and EGFR. Luciferase assays were carried out to determine the activity of CYP1B1 promoter deletion constructs upon 3MC exposure, while the nuclear shuttle of AHR induced by 3MC was assessed through confocal microscopy. Cell proliferation stimulated by 3MC was determined as biological counterpart of the aforementioned experimental assays. The statistical analysis was performed by ANOVA. We first ascertained by docking simulations the ability of 3MC to interact with GPER. Thereafter, we established that 3MC activates the EGFR/ERK/c-Fos transduction signaling through both AHR and GPER in SkBr3 cells and CAFs. Then, we found that these receptors are involved in the up-regulation of CYP1B1 and cyclin D1 as well as in the stimulation of growth responses induced by 3MC. In the present study we have provided novel insights regarding the molecular mechanisms by which 3MC may trigger a physical and functional interaction between AHR and GPER, leading to the stimulation of both SkBr3 breast cancer cells and CAFs. Altogether, our results indicate that 3MC may engage both GPER and AHR transduction pathways toward breast cancer progression.

Sections du résumé

BACKGROUND BACKGROUND
The chemical carcinogen 3-methylcholanthrene (3MC) binds to the aryl hydrocarbon receptor (AHR) that regulates the expression of cytochrome P450 (CYP) enzymes as CYP1B1, which is involved in the oncogenic activation of environmental pollutants as well as in the estrogen biosynthesis and metabolism. 3MC was shown to induce estrogenic responses binding to the estrogen receptor (ER) α and stimulating a functional interaction between AHR and ERα. Recently, the G protein estrogen receptor (GPER) has been reported to mediate certain biological responses induced by endogenous estrogens and environmental compounds eliciting an estrogen-like activity.
METHODS METHODS
Molecular dynamics and docking simulations were performed to evaluate the potential of 3MC to interact with GPER. SkBr3 breast cancer cells and cancer-associated fibroblasts (CAFs) derived from breast tumor patients were used as model system. Real-time PCR and western blotting analysis were performed in order to evaluate the activation of transduction mediators as well as the mRNA and protein levels of CYP1B1 and cyclin D1. Co-immunoprecipitation studies were performed in order to explore the potential of 3MC to trigger the association of GPER with AHR and EGFR. Luciferase assays were carried out to determine the activity of CYP1B1 promoter deletion constructs upon 3MC exposure, while the nuclear shuttle of AHR induced by 3MC was assessed through confocal microscopy. Cell proliferation stimulated by 3MC was determined as biological counterpart of the aforementioned experimental assays. The statistical analysis was performed by ANOVA.
RESULTS RESULTS
We first ascertained by docking simulations the ability of 3MC to interact with GPER. Thereafter, we established that 3MC activates the EGFR/ERK/c-Fos transduction signaling through both AHR and GPER in SkBr3 cells and CAFs. Then, we found that these receptors are involved in the up-regulation of CYP1B1 and cyclin D1 as well as in the stimulation of growth responses induced by 3MC.
CONCLUSIONS CONCLUSIONS
In the present study we have provided novel insights regarding the molecular mechanisms by which 3MC may trigger a physical and functional interaction between AHR and GPER, leading to the stimulation of both SkBr3 breast cancer cells and CAFs. Altogether, our results indicate that 3MC may engage both GPER and AHR transduction pathways toward breast cancer progression.

Identifiants

pubmed: 31370872
doi: 10.1186/s13046-019-1337-2
pii: 10.1186/s13046-019-1337-2
pmc: PMC6676524
doi:

Substances chimiques

AHR protein, human 0
Basic Helix-Loop-Helix Transcription Factors 0
GPER1 protein, human 0
Receptors, Aryl Hydrocarbon 0
Receptors, Estrogen 0
Receptors, G-Protein-Coupled 0
Methylcholanthrene 56-49-5
CYP1B1 protein, human EC 1.14.14.1
Cytochrome P-450 CYP1B1 EC 1.14.14.1
EGFR protein, human EC 2.7.10.1
ErbB Receptors EC 2.7.10.1
Extracellular Signal-Regulated MAP Kinases EC 2.7.11.24

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

335

Subventions

Organisme : AIRC
ID : IG 21322

Références

J Biol Chem. 2001 Jan 5;276(1):662-9
pubmed: 11024050
Environ Health Perspect. 2002 Jun;110 Suppl 3:451-88
pubmed: 12060843
Chem Biol Interact. 2002 Sep 20;141(1-2):117-30
pubmed: 12213388
Nature. 2003 May 29;423(6939):545-50
pubmed: 12774124
J Biochem. 2003 May;133(5):583-92
pubmed: 12801909
J Comput Chem. 2004 Jul 15;25(9):1157-74
pubmed: 15116359
Cancer Res. 2004 May 1;64(9):3119-25
pubmed: 15126349
Environ Health Perspect. 2004 Jun;112(9):970-8
pubmed: 15198916
Endocrinology. 2005 Feb;146(2):624-32
pubmed: 15539556
Cancer Lett. 2005 Sep 28;227(2):115-24
pubmed: 16112414
J Cell Biochem. 2005 Dec 15;96(6):1174-84
pubmed: 16211578
Toxicol Appl Pharmacol. 2006 Jun 1;213(2):87-97
pubmed: 16257430
Cancer Res. 2006 Feb 15;66(4):2459-67
pubmed: 16489053
Nat Chem Biol. 2006 Apr;2(4):207-12
pubmed: 16520733
Nucl Recept Signal. 2006;4:e016
pubmed: 16862222
Ann Oncol. 2007 Mar;18(3):431-46
pubmed: 16936186
Biol Chem. 2006 Sep;387(9):1209-13
pubmed: 16972788
J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):175-9
pubmed: 17088055
Nat Rev Cancer. 2006 Dec;6(12):947-60
pubmed: 17128211
Bioorg Med Chem. 2007 Aug 1;15(15):5047-60
pubmed: 17544277
Mol Pharmacol. 2008 Feb;73(2):575-86
pubmed: 18003862
Endocrinology. 2008 Aug;149(8):3799-808
pubmed: 18467441
Crit Rev Eukaryot Gene Expr. 2008;18(3):207-50
pubmed: 18540824
Biochem Pharmacol. 2009 Feb 15;77(4):713-22
pubmed: 18817753
Biochem Pharmacol. 2009 Feb 15;77(4):508-20
pubmed: 18848820
Cancer Prev Res (Phila). 2008 Nov;1(6):485-93
pubmed: 19138996
EMBO J. 2009 Mar 4;28(5):523-32
pubmed: 19153601
J Comput Chem. 2009 Dec;30(16):2785-91
pubmed: 19399780
Mol Cell Endocrinol. 2009 Sep 24;308(1-2):32-8
pubmed: 19464786
J Comput Chem. 2010 Jan 30;31(2):455-61
pubmed: 19499576
Gynecol Oncol. 2009 Sep;114(3):465-71
pubmed: 19501895
Mol Endocrinol. 2009 Nov;23(11):1815-26
pubmed: 19749156
J Endocrinol. 2010 Feb;204(2):105-14
pubmed: 19767412
Cancer Res. 2010 Feb 1;70(3):1184-94
pubmed: 20086172
Carcinogenesis. 2010 Aug;31(8):1319-28
pubmed: 20106901
Mol Cell Endocrinol. 2010 May 14;320(1-2):162-70
pubmed: 20138962
J Exp Clin Cancer Res. 2010 Feb 24;29:16
pubmed: 20181250
Proteins. 2010 Jun;78(8):1950-8
pubmed: 20408171
J Exp Clin Cancer Res. 2010 Jun 08;29:66
pubmed: 20529313
Cancer Res. 2010 Jul 15;70(14):6036-46
pubmed: 20551055
J Exp Clin Cancer Res. 2010 Jun 22;29:80
pubmed: 20569497
Toxicol Sci. 2010 Oct;117(2):393-403
pubmed: 20634293
IARC Monogr Eval Carcinog Risks Hum. 2010;92:1-853
pubmed: 21141735
J Steroid Biochem Mol Biol. 2011 Nov;127(3-5):358-66
pubmed: 21782022
J Exp Clin Cancer Res. 2011 Oct 20;30:99
pubmed: 22014025
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2011 Oct;29(4):324-57
pubmed: 22107166
Breast Cancer Res Treat. 2012 Jun;133(3):1025-35
pubmed: 22147081
Breast Cancer Res. 2012 Jan 17;14(1):R12
pubmed: 22251451
Am J Physiol Gastrointest Liver Physiol. 2012 May 1;302(9):G1006-15
pubmed: 22361730
Curr Cancer Drug Targets. 2012 Jun;12(5):531-42
pubmed: 22414008
Environ Health Perspect. 2012 Aug;120(8):1177-82
pubmed: 22552965
J Exp Clin Cancer Res. 2012 May 03;31:42
pubmed: 22553917
Cancer Lett. 2012 Nov 1;324(1):13-30
pubmed: 22561558
J Exp Clin Cancer Res. 2012 May 16;31:46
pubmed: 22592002
Clin Epigenetics. 2011 Aug;2(2):63-76
pubmed: 22704330
Mol Carcinog. 2014 Oct;53(10):765-76
pubmed: 23625689
Biochim Biophys Acta. 2013 Dec;1836(2):197-210
pubmed: 23711559
Mol Cancer Ther. 2013 Aug;12(8):1492-503
pubmed: 23723126
Toxicol Sci. 2013 Sep;135(1):1-16
pubmed: 23771949
Environ Int. 2013 Oct;60:71-80
pubmed: 24013021
Mol Nutr Food Res. 2014 Mar;58(3):478-89
pubmed: 24019118
Molecules. 2013 Nov 25;18(12):14470-95
pubmed: 24287985
J Cancer Res Clin Oncol. 2014 Apr;140(4):663-71
pubmed: 24515910
J Cancer Res Clin Oncol. 2014 May;140(5):713-23
pubmed: 24553912
PLoS One. 2014 Apr 22;9(4):e95058
pubmed: 24755659
J Agric Food Chem. 2014 May 14;62(19):4384-91
pubmed: 24773207
Mol Cancer Res. 2014 Nov;12(11):1644-1654
pubmed: 25030371
J Steroid Biochem Mol Biol. 2015 Mar;147:24-30
pubmed: 25448748
Nat Rev Cancer. 2014 Dec;14(12):801-14
pubmed: 25568920
J Biomol Struct Dyn. 2015;33(10):2161-72
pubmed: 25587872
Environ Health Perspect. 2015 May;123(5):493-9
pubmed: 25616260
Future Med Chem. 2015;7(4):437-48
pubmed: 25875871
Toxicol Sci. 2015 May;145(1):5-15
pubmed: 25911656
Pestic Biochem Physiol. 2015 May;120:5-13
pubmed: 25987214
Pharmacol Rev. 2015 Jul;67(3):505-40
pubmed: 26023144
Structure. 2015 Aug 4;23(8):1538-1549
pubmed: 26190572
Cell Death Dis. 2015 Jul 30;6:e1834
pubmed: 26225773
Mol Inform. 2013 Jul;32(7):647-658
pubmed: 26229572
Cancers (Basel). 2015 Jul 31;7(3):1436-46
pubmed: 26264025
J Exp Clin Cancer Res. 2015 Oct 06;34:111
pubmed: 26445347
Oncotarget. 2016 Jan 5;7(1):94-111
pubmed: 26646587
Breast Care (Basel). 2015 Oct;10(5):316-8
pubmed: 26688678
Environ Int. 2016 Apr-May;89-90:185-92
pubmed: 26878284
Clin Transl Med. 2016 Mar;5(1):12
pubmed: 26979321
PLoS One. 2016 Mar 16;11(3):e0151598
pubmed: 26981862
Sci Rep. 2016 Apr 13;6:24354
pubmed: 27072893
Mol Carcinog. 2017 Feb;56(2):580-593
pubmed: 27341075
Oncotarget. 2016 Aug 16;7(33):52710-52728
pubmed: 27384677
J Immunol. 2016 Dec 15;197(12):4639-4650
pubmed: 27849171
Phys Chem Chem Phys. 2016 Nov 30;18(47):32358-32368
pubmed: 27854368
J Steroid Biochem Mol Biol. 2018 Feb;176:49-56
pubmed: 28249728
J Biochem. 2018 Mar 1;163(3):223-232
pubmed: 29092071
Cancer Treat Rev. 2018 Feb;63:1-18
pubmed: 29197745
Clin Cancer Res. 2018 Mar 1;24(5):1227-1239
pubmed: 29229632
Oncotarget. 2017 Nov 20;8(63):106608-106624
pubmed: 29290975
J Toxicol Environ Health A. 2018;81(9):278-287
pubmed: 29473798
J Exp Clin Cancer Res. 2018 May 2;37(1):94
pubmed: 29716623
Int J Mol Sci. 2018 May 07;19(5):null
pubmed: 29735912
Biochim Open. 2018 Jun 11;7:1-9
pubmed: 30003042
Toxicol Sci. 2018 Oct 1;165(2):447-461
pubmed: 30137621
J Exp Clin Cancer Res. 2018 Nov 26;37(1):282
pubmed: 30477536
Environ Int. 2019 Mar;124:109-120
pubmed: 30641254
J Exp Clin Cancer Res. 2019 Feb 6;38(1):58
pubmed: 30728047
J Biol Chem. 1996 Nov 8;271(45):28324-30
pubmed: 8910454

Auteurs

Francesca Cirillo (F)

Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Cosenza, Rende, Italy.

Rosamaria Lappano (R)

Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Cosenza, Rende, Italy.

Leonardo Bruno (L)

Department of Biology, Ecology and Earth Sciences, University of Calabria, 87036, Rende, Italy.

Bruno Rizzuti (B)

CNR-NANOTEC, Licryl-UOS Cosenza and CEMIF. Cal and Department of Physics, University of Calabria, 87036, Rende, Italy.

Fedora Grande (F)

Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Cosenza, Rende, Italy.

Rita Guzzi (R)

CNR-NANOTEC, Licryl-UOS Cosenza and CEMIF. Cal and Department of Physics, University of Calabria, 87036, Rende, Italy.
Molecular Biophysics Laboratory, Department of Physics, University of Calabria, 87036, Rende, Italy.

Sara Briguori (S)

Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Cosenza, Rende, Italy.

Anna Maria Miglietta (AM)

Regional Hospital Cosenza, 87100, Cosenza, Italy.

Miki Nakajima (M)

Drug Metabolism and Toxicology, WPI Nano Life Science Institute, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan.

Maria Teresa Di Martino (MT)

Department of Experimental and Clinical Medicine, Magna Graecia University, 88100, Catanzaro, Italy. teresadm@unicz.it.

Marcello Maggiolini (M)

Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Cosenza, Rende, Italy. marcellomaggiolini@yahoo.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH